Characteristic | N (%) |
Age | Median 53 years (range 23–71) |
Gender | |
Male | 37 (52.1) |
Female | 34 (47.9) |
Smoker | |
Never | 61 (86.1) |
Smoker | 8 (11.1) |
Ex-smoker | 2 (2.8) |
ECOG PS | |
1–2 | 61 (86.1) |
3–4 | 10 (13.4) |
Histology | |
Adenocarcinoma | 68 (95.8) |
Squamous cell carcinoma | 2 (2.8) |
Sarcomatoid carcinoma | 1 (1.4) |
ALK TKI | 60 |
Crizotinib | 43 |
Ceritinib | 7 |
Alectinib | 10 |
No TKI | 11 |
ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; PS, performance status; TKI, tyrosine kinase inhibitor.